Breaking News Instant updates and real-time market news.

VRX

Valeant

$15.64

0.27 (1.76%)

06:10
08/09/17
08/09
06:10
08/09/17
06:10

Valeant price target raised to $14 from $10 at Piper Jaffray

Piper Jaffray analyst David Amsellem raised his price target for Valeant Pharmaceuticals to $14 saying the company's Q2 earnings report contained some bright spots. Performance from Xifaxan as well as Bausch and Lomb was "solid," Amsellem tells investors in a research note. The analyst, however, reiterates an Underweight rating on the shares. Valeant's debt levels remain "exceedingly high" and its EBITDA is likely to decline in 2018, the analyst argues.

  • 24

    Aug

VRX Valeant
$15.64

0.27 (1.76%)

07/27/17
WELS
07/27/17
NO CHANGE
WELS
Underperform
Doctors not optimistic about Valeant's Siliq, says Wells Fargo
Wells Fargo analyst David Maris says the dozens of doctors he spoke to about Valeant Pharmaceuticals' Siliq are not optimistic. Over 50% of the physicians surveyed said they would use Siliq only as a fourth line therapy or later, Maris tells investors in a research note after Valeant announced the launch of the moderate-to-severe plaque psoriasis treatment. The analyst disagrees with Valeant management's claims that Siliq has "very large peak sales potential." The injection carries a warning about risk of suicide and Valeant will be competing against a large number of peers with greater resources, Maris argues. The analyst has an Underperform rating on Valeant shares, which are down 18c to $17.59 in midday trading.
07/28/17
WELS
07/28/17
NO CHANGE
Target $9
WELS
Underperform
Insurers are dropping Valeant's top products, says Wells Fargo
United Healthcare's (UNH) formulary is no longer covering Valeant Pharmaceuticals' (VRX) number three branded drug Solodyn and will also now exclude Retin-A brand, its number four branded drug, Wells Fargo analyst David Maris tells investors in a research note. The analyst estimates the two drugs represented approximately $214M of Valeant's sales in 2016. Maris also points out that Glumetza, Valeant's number eight branded drug, and Relistor were removed in July from CVS/Caremark's (CVS) formulary. These two drugs had approximately $119M in 2016 revenues. Maris notes his counterpart Peter Costa estimates that United Healthcare covers approximately 17% of the U.S. and CVS covers approximately 33%. Express Scripts (ESRX) is releasing its 2018 national formulary next week, Costa adds. Maris keeps an Underperform rating on shares of Valeant with a $9 price target. The stock in premarket trading is down 33c, or 2%, to $16.80.
08/04/17
WELS
08/04/17
NO CHANGE
WELS
Underperform
Valeant's Isuprel to face generic from Nexus, says Wells Fargo
Wells Fargo analyst David Maris noted that the FDA is reporting, and Nexus Pharmaceuticals has confirmed to him, that the company received approval for a generic version of Valeant's Isuprel. Nexus expects to "command the lion's share" of the U.S. market for the drug, as its version is made in the U.S. and has longer stability than Valeant's version, Maris tells investors. The analyst, who notes that Valeant previously indicated it anticipated that Isuprel would lose exclusivity in Q4, keeps an Underperform rating on the stock.
08/08/17
WELS
08/08/17
NO CHANGE
WELS
Underperform
Wells' Maris says Valeant Q2 report 'doesn't look good'
Wells Fargo analyst David Maris, who has a long-standing Underperform rating on Valeant, noted the company's Q2 GAAP EPS of (11c) and that its reported revenues were down 8% compared to the same quarter of last year. Valeant's adjusted EBITDA of $951M missed his $983M estimate and its leverage ratio has not materially improved, but has in fact worsened, said Maris, who continues to believe the "longer-term outlook for Valeant is not promising."

TODAY'S FREE FLY STORIES

16:37
11/24/17
11/24
16:37
11/24/17
16:37
General news
Money Supply M2 Weekly Change data reported »

Week of 11/13 Money…

16:37
11/24/17
11/24
16:37
11/24/17
16:37
General news
Fed Balance Sheet Level data reported »

Week of 11/22 Fed Balance…

$NSD

NASDAQ Market Internals

16:17
11/24/17
11/24
16:17
11/24/17
16:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

16:16
11/24/17
11/24
16:16
11/24/17
16:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:15
11/24/17
11/24
16:15
11/24/17
16:15
General news
Breaking General news story  »

Week of 11/13 Money…

16:15
11/24/17
11/24
16:15
11/24/17
16:15
General news
Breaking General news story  »

Week of 11/22 Fed Balance…

RIC

Richmont Mines

16:01
11/24/17
11/24
16:01
11/24/17
16:01
Hot Stocks
Breaking Hot Stocks news story on Richmont Mines »

Richmont Mines trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGLN

Magellan Health

$83.65

0.35 (0.42%)

15:18
11/24/17
11/24
15:18
11/24/17
15:18
Conference/Events
Magellan Health to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Dec

SGMS

Scientific Games

$52.00

-0.2 (-0.38%)

15:17
11/24/17
11/24
15:17
11/24/17
15:17
Conference/Events
Scientific Games to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

15:17
11/24/17
11/24
15:17
11/24/17
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

15:16
11/24/17
11/24
15:16
11/24/17
15:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

14:17
11/24/17
11/24
14:17
11/24/17
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
11/24/17
11/24
14:16
11/24/17
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

M

Macy's

$21.07

0.44 (2.13%)

, WMT

Wal-Mart

$96.62

0.21 (0.22%)

13:29
11/24/17
11/24
13:29
11/24/17
13:29
General news
On The Fly: Top stock stories for Friday »

Stocks on Wall Street…

M

Macy's

$21.07

0.44 (2.13%)

WMT

Wal-Mart

$96.62

0.21 (0.22%)

TGT

Target

$55.88

-1.61 (-2.80%)

BASFY

BASF

$27.39

-0.13 (-0.47%)

TEVA

Teva

$13.70

0.22 (1.63%)

CBS

CBS

$56.54

0.3 (0.53%)

DISH

Dish

$50.43

0.39 (0.78%)

ASX

Advanced Semiconductor

$7.07

0.76 (12.04%)

SPIL

Siliconware Precision

$7.94

-0.05 (-0.63%)

QD

Qudian

$12.22

-3.93 (-24.33%)

BABA

Alibaba

$191.19

1.35 (0.71%)

VIPS

Vipshop

$8.14

-0.3 (-3.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Nov

  • 20

    Feb

  • 18

    Mar

AFL

Aflac

$85.00

-0.05 (-0.06%)

13:26
11/24/17
11/24
13:26
11/24/17
13:26
Conference/Events
Aflac to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Dec

GBL

GAMCO Investors

, WTS

Watts Water

$72.65

0.15 (0.21%)

13:26
11/24/17
11/24
13:26
11/24/17
13:26
Hot Stocks
Breaking Hot Stocks news story on GAMCO Investors, Watts Water »

Gabelli reports 6.69%…

GBL

GAMCO Investors

WTS

Watts Water

$72.65

0.15 (0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

CC

Chemours

$53.31

0.45 (0.85%)

13:23
11/24/17
11/24
13:23
11/24/17
13:23
Conference/Events
Chemours to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Dec

$NSD

NASDAQ Market Internals

13:17
11/24/17
11/24
13:17
11/24/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

13:16
11/24/17
11/24
13:16
11/24/17
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIMT

Aimmune

$35.74

0.16 (0.45%)

13:09
11/24/17
11/24
13:09
11/24/17
13:09
Conference/Events
Aimmune to hold an investor symposium »

Investor Symposium…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

PN

Patriot National

12:57
11/24/17
11/24
12:57
11/24/17
12:57
Hot Stocks
Breaking Hot Stocks news story on Patriot National »

Patriot National trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMCM

Cheetah Mobile

$12.02

-0.4 (-3.22%)

12:55
11/24/17
11/24
12:55
11/24/17
12:55
Options
Cheetah Mobile put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$44.47

0.1828 (0.41%)

12:53
11/24/17
11/24
12:53
11/24/17
12:53
Conference/Events
General Motors holds an investor an analyst webcast »

Management hosts a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

  • 09

    Jan

  • 16

    Jan

12:45
11/24/17
11/24
12:45
11/24/17
12:45
General news
Breaking General news story  »

Week of 11/24…

EBAY

eBay

$35.94

-0.02 (-0.06%)

, OSTK

Overstock.com

$61.05

0.6 (0.99%)

12:43
11/24/17
11/24
12:43
11/24/17
12:43
Periodicals
Adobe: Black Friday online sales up 18.4% y/y as of 10:00 am ET, CNBC says »

According to Adobe…

EBAY

eBay

$35.94

-0.02 (-0.06%)

OSTK

Overstock.com

$61.05

0.6 (0.99%)

AMZN

Amazon.com

$1,156.16

16.67 (1.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 18

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.